iBio announces production of vaccine candidate for new H7N9 influenza virus

iBio, Inc. (NYSE MKT: IBIO) today announced the production of a vaccine candidate for the newly emerged H7N9 influenza virus by an independent third party laboratory using the iBioLaunch™ platform. This validation milestone was achieved in 21 days as measured from initial antigen sequence information to purification of recombinant protein.

The iBioLaunch platform eliminates the need to culture cells under sterile conditions, removes uncertainty about yield consistency for large volumes of production, and, subject to regulatory approval, could deliver vaccine doses for emergency use against pandemic and bioterrorism threats in weeks rather than the months necessary with the use of engineered or attenuated virus strains.  The iBioLaunch platform has been used previously to produce vaccine-quality antigens associated with a broad range of influenza strains including H7N7, H5N1, H3N2, H1N1, and various strains of influenza B.  

These vaccine applications of the iBioLaunch platform are of particular interest to governments and state corporations that seek autonomy in the manufacture of critical biopharmaceuticals to protect their own populations.


iBio, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Scientists investigate relevance of COVID-19 vaccine-mediated T cell immunity to SARS-CoV-2 variants